Franklyn G. Prendergast

Insider Reports History

Entity
Individual
Signature
/s/ Sandra Stoneman, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Franklyn G. Prendergast:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Immunome Inc. Director Common Stock 60.8K $360K $5.91 Oct 2, 2023 Direct
Immunome Inc. Director Stock Option (Right to Buy) 138K Oct 2, 2023 Direct
NeuBase Therapeutics, Inc. Director Stock option (right to buy) 37.6K Sep 9, 2022 Direct
Lantern Pharma Inc. Director Stock Option (Right to Buy) 3.2K Nov 4, 2021 Direct

Insider Reports Filed by Franklyn G. Prendergast

Symbol Company Period Transactions Value $ Form Type Date Filed Role
IMNM Immunome Inc. Oct 2, 2023 2 $186K 4 Oct 4, 2023 Director
IMNM Immunome Inc. Jun 8, 2023 1 $0 4 Jun 12, 2023 Director
NBSE NeuBase Therapeutics, Inc. Sep 9, 2022 1 $0 4 Sep 12, 2022 Director
IMNM Immunome Inc. Jun 16, 2022 1 $0 4 Jun 21, 2022 Director
LTRN Lantern Pharma Inc. Nov 4, 2021 1 $0 4 Nov 8, 2021 Director
NBSE NeuBase Therapeutics, Inc. Aug 19, 2021 1 $0 4 Sep 17, 2021 Director
IMNM Immunome Inc. Jun 16, 2021 1 $0 4 Jun 21, 2021 Director
IMNM Immunome Inc. Jun 16, 2021 0 $0 3 Jun 21, 2021 Director